

CASE LA0046a CIP-1

REMARKS

The Examiner has requested that Applicant amend Claim 58 to include glyburide distribution as set out in Claim 37. Claim 58 has been amended accordingly.

In view of the above amendment and the previous submissions, it is believed that Claims 37, 45 to 54, 58 to 60, 71 to 73 and 75 to 79 are in condition for allowance.

Respectfully submitted,



Burton Rodney
Attorney for Applicant
Reg. No. 22,076

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4336

Date: February 4, 2003



CASE LA0046a CIP-1

MARKED UP VERSION TO SHOW CHANGES

-- 58. (Amended) A method for first line treatment of type 2 diabetes, in a drug naïve human patient, which comprises administering to a drug naïve human patient in need of treatment, as first line therapy, a low dose of a combination of metformin and glyburide wherein the starting daily dosage is 250 mg metformin and 1.25 mg glyburide where the glyburide has a particle size distribution so that at most 10% of the particles of glyburide are less than 2 µm and at most 10% of the particles of glyburide are greater than 60 µm. --

E